Filing Overview
Registrant: Tivic Health Systems, Inc., although the request metadata identifies Valion Bio, Inc. The filing should be verified against the intended company.
Form 8-K date: December 21, 2022. The filing was submitted under Section 13 or 15(d) of the Securities Exchange Act of 1934. Tivic’s common stock traded on Nasdaq under the symbol TIVC.
Business Context and Reporting Period
The filing reports that Tivic began using a new corporate presentation on December 21, 2022. The presentation was furnished as Exhibit 99.1 and was also made available through the company’s investor website. The filing does not provide a financial reporting period or operating results.
Financial and Operating Metrics
- Revenue, net income, cash flow, margins, debt, liquidity, cash balance, and other financial metrics are not provided in the filing text.
- No quantitative operating targets or performance metrics are disclosed in the filing text.
Material Changes Versus Prior Period
The filing does not report changes in revenue, profitability, cash flow, capital structure, liquidity, or operations versus a prior comparable period. The only disclosed event is the launch of a new corporate presentation.
Guidance, Outlook, Risks, and Unusual Items
- The filing contains forward-looking statement disclaimers concerning anticipated, expected, estimated, believed, or future results.
- Management identifies general risks and uncertainties that could cause actual operating or financial results to differ materially from forward-looking statements, but the filing text does not specify company-level guidance or quantified risks.
- Information under Item 7.01 and Exhibit 99.1 was furnished, not filed, and is not subject to Section 18 liability or incorporated by reference into other filings except by specific reference.
- No unusual accounting items, contingencies, litigation matters, financing transactions, or other material events are disclosed in the provided text.
Key Facts for Investor Verification
- Confirm that Tivic Health Systems, Inc., rather than Valion Bio, Inc., is the intended registrant.
- Review Exhibit 99.1, the December 2022 corporate presentation, for any business outlook, commercial information, or financial claims not included in the filing text.
- Verify that all statements in the presentation are furnished Regulation FD materials and are not incorporated by reference unless expressly stated in a subsequent filing.
- Consult the company’s periodic reports for revenue, cash runway, liquidity, debt, operating losses, and other financial information absent from this 8-K.